With stabilizing interest rates and increased FDA activity, three biotech companies stand out: Schrödinger combines AI-driven drug discovery with established software revenue ($256M in 2025); Sarepta generates nearly $2B in annual product revenue from gene therapy despite ongoing safety concerns around Elevidys; and NRX Pharmaceuticals, a speculative small-cap, has regulatory momentum with FDA decisions expected this summer for depression and suicidality treatments.

The global protein synthesis research market is experiencing accelerating growth driven by increased investment in cell and gene therapy research, rising chronic disease prevalence, and expanding healthcare budgets. North America leads with 42.8% market share, while Asia-Pacific infrastructure expansion presents significant growth opportunities. Key market drivers include strong late-stage therapy pipelines and government support through initiatives like the CHIPS and Science Act.

U.S. equities tumbled to their lowest levels in nearly seven months on Friday as the Nasdaq 100 officially entered correction territory, down over 10% from January highs. The decline was driven by geopolitical tensions with Iran rejecting ceasefire options, surging crude oil prices, deteriorating consumer sentiment, and rising inflation expectations. The 30-year Treasury yield climbed to 4.958%, threatening to breach 5% for the first time since July 2025, while the Fed rate hike probability by December jumped to nearly 50%.

U.S. stock futures declined on Monday as investors await mega-cap earnings from tech giants and other major companies. The market is also bracing for the Federal Reserve's interest rate decision on Wednesday, with markets pricing in a 97.2% likelihood of unchanged rates. Key movers include Baker Hughes (up on strong Q4 results), Sarepta Therapeutics (up on trial completion), and Brand Engagement Network (surging 221% on strategic partnership announcement). Analyst Mohamed El-Erian highlights the '2025 Paradox' of resilient markets amid geopolitical tensions.

Sarepta Therapeutics and Teladoc Health are identified as two stocks likely to continue declining in 2026. Sarepta faces significant headwinds from safety concerns with its flagship DMD treatment Elevidys, which caused patient deaths and led to restricted access. Teladoc Health struggles with slowing revenue growth, mounting losses, and increased competition in the telemedicine space, particularly affecting its BetterHelp platform.

Wall Street traded modestly higher Tuesday with the S&P 500 up 0.4% near 6,900. Strong U.S. GDP data (4.3% annualized growth) prompted traders to scale back Fed rate cut expectations. Novo Nordisk surged 9% following FDA approval of Wegovy in pill form. Precious metals rallied significantly, with silver jumping over 2% to break above $70/ounce (up 140% YTD), gold reaching record highs, and platinum surging 5.5%.

Sarepta Therapeutics experienced a significant stock drop of over 33% after its Phase 3 ESSENCE study for Duchenne muscular dystrophy treatments failed to meet primary endpoints, raising concerns about its drug pipeline and gene therapy safety.

The AAV gene therapy market is projected to grow from $3.85 billion in 2025 to $78.56 billion by 2034, with a 40.1% CAGR. North America leads the market, driven by research investments, technological advancements, and increasing genetic disorder prevalence.

The article analyzes two healthcare stocks, Teladoc and Sarepta Therapeutics, highlighting significant challenges that make them unattractive investment options, including revenue decline, profitability issues, and safety concerns with medical treatments.

Sarepta Therapeutics faces a class action lawsuit alleging misleading investors about safety risks of its ELEVIDYS gene therapy for Duchenne muscular dystrophy, with two patient deaths and FDA investigation leading to significant stock price drops.

The genetic material market is expected to experience substantial growth driven by advancements in gene therapies, personalized medicine, and biopharmaceutical research. North America leads the market in 2024, with Asia Pacific projected to be the fastest-growing region from 2025-2034.

The Schall Law Firm is pursuing a class action lawsuit against Sarepta Therapeutics for allegedly making false and misleading statements about its ELEVIDYS therapy's safety, potential, and revenue outlook between June 2023 and June 2025.